MSLN and cancer: The results demonstrate that the frequency of circulating anti-MSLN specific CD4+ T cells in cancer patients were significantly higher than that observed in the benign pancreatic disease patients (p = 0.0053) and normal controls (p = 0.0004, Figure 4B).